Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between duvelisib and VazoTuss HC

Results for the following 2 drugs:
duvelisib
VazoTuss HC (brompheniramine/hydrocodone/phenylephrine)

Interactions between your drugs

Moderate

HYDROcodone duvelisib

Applies to: VazoTuss HC (brompheniramine / hydrocodone / phenylephrine) and duvelisib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. When a single 2 mg oral dose of midazolam, a sensitive CYP450 3A4 substrate, was administered to 14 healthy adult study subjects following multiple doses of duvelisib 25 mg twice daily for 5 days, midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.2- and 4.3-fold, respectively.

MANAGEMENT: Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever duvelisib is added to or withdrawn from therapy.

References

  1. "Product Information. Copiktra (duvelisib)." Verastem, Inc., Needham, MA.

Drug and food interactions

Major

HYDROcodone food

Applies to: VazoTuss HC (brompheniramine / hydrocodone / phenylephrine)

Do not use alcohol or medications that contain alcohol while you are receiving treatment with HYDROcodone. This may increase nervous system side effects such as drowsiness, dizziness, lightheadedness, difficulty concentrating, and impairment in thinking and judgment. In severe cases, low blood pressure, respiratory distress, fainting, coma, or even death may occur. If you are taking certain long-acting formulations of hydrocodone, consumption of alcohol may also cause rapid release of the drug, resulting in high blood levels that may be potentially lethal. Likewise, you should avoid consuming grapefruit and grapefruit juice, as this may increase the blood levels and effects of hydrocodone. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. Do not use more than the recommended dose of HYDROcodone, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.

Switch to professional interaction data

Moderate

brompheniramine food

Applies to: VazoTuss HC (brompheniramine / hydrocodone / phenylephrine)

Alcohol can increase the nervous system side effects of brompheniramine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with brompheniramine. Do not use more than the recommended dose of brompheniramine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide